Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Conditions
Gastric or Gastroesophageal Junction Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancer (BTC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
University of Iowa, Iowa City, Iowa, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
Duke Cancer Center, Durham, North Carolina, United States
University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center, GI Medical Oncology Dept, Houston, Texas, United States
NEXT Oncology, Fairfax, Virginia, United States
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States